Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

被引：0
|
作者：
Landi, Lorenza [1 ]
Cappuzzo, Federico [1 ]
机构：
[1] Osped Civile Livorno, Ist Toscano Tumori, I-57100 Livorno, Italy
来源：
JOURNAL OF THORACIC DISEASE | 2012年 / 4卷 / 02期
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; GEFITINIB;
D O I：
10.3978/j.issn.2072-1739.2012.03.04
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：226 / 228
页数：3
相关论文
共 50 条
  • [41] A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
    Yoh, Kiyotaka
    Azuma, Koichi
    Hayashi, Hidetoshi
    Nishio, Makoto
    Chikamori, Kenichi
    Ichihara, Eiki
    Watanabe, Yasutaka
    Asato, Takayuki
    Kitagawa, Tadayuki
    Fram, Robert J.
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1461 - 1474
  • [42] Genetic Testing in Breast Cancer Patients: Do Mutations Other than BRCA Make a Difference in Surgical Decision Making?
    Beck, A. C.
    Imperiale-Hagerman, P.
    Shipley, K.
    Erdahl, L.
    Sugg, S. L.
    Weigel, R. J.
    Lizarraga, I. M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S96 - S96
  • [43] When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?
    Heisler, M
    Vijan, S
    Anderson, RM
    Ubel, PA
    Bernstein, SJ
    Hofer, TP
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 (11) : 893 - 902
  • [44] When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?
    Michele Heisler
    Sandeep Vijan
    Robert M. Anderson
    Peter A. Ubel
    Steven J. Bernstein
    Timothy P. Hofer
    Journal of General Internal Medicine, 2003, 18 : 893 - 902
  • [45] When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?
    Heisler, M
    Vijan, S
    Anderson, RM
    Ubel, PA
    Bernstein, SJ
    Hofer, TP
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 284 - 284
  • [46] Gefitinib in First-Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21
    Skrickova, Jana
    Hejduk, Karel
    Bortlicek, Zbynek
    Pesek, Milos
    Kolek, Viterslav
    Koubkova, Leona
    Grygarkova, Ivona
    Cernovska, Marketa
    Havel, Libor
    Tomiskova, Marcela
    Zemanova, Milada
    Roubec, Jaromir
    Sixtova, Dimka
    Coupkova, Helena
    Satankova, Monika
    Benejova, Andrea
    Hrnciarik, Michal
    Marel, Miloslav
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1240 - S1241
  • [47] Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
    Yang, J. C-H.
    Wang, M.
    Chiu, C-H.
    Hsu, P-C.
    Mitchell, P.
    Chang, C. L.
    Kim, T. M.
    John, T.
    Greillier, L.
    Bazhenova, L.
    Carcereny, E.
    Spira, A. I.
    Shim, B.
    Lee, K. H.
    Cobo Dols, M.
    Ghiringhelli, F.
    Yip, C. W.
    Xiong, J.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] Impact of the first-line treatment on the clinical course in Japanese NSCLC patients with EGFR mutations.
    Sakamori, Yuichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip J.
    Yang, Jia-Lin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5461 - 5473
  • [50] Treatment Pattern and Real World Effectiveness on Non Small Cell Lung Cancer Patients Harboring Major Single and Double EGFR Mutations
    So, W. Venus
    Yang, Xing
    Leddin, Mathias
    Chen, Lin-Chi
    Nagel, Yvonne A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 44 - 45
12345